In patients with chronic liver disease, IL-33 acts as a chemotactic agent for Th2, inducing type 2 polarization of CD4+T cells, thereby promoting liver fibrosis (104), Th2 cytokines, such as IL-6, IL-4, and IL-13, promoting the formation of fibrosis (105). This evidence concerns the gene IL33 and Hepatic fibrosis.